Appendix 4E and 2023 Annual Report
Filed with ASX · · 80 pages · English
Summary by 6ix AI
The report indicates a loss from ordinary activities after tax attributable to the owners of Patrys Limited, reflecting an increase compared to the previous year. No dividends were declared or paid during the current financial period, and the company reported a decrease in cash reserves compared to the prior year. The report also highlights ongoing developments in the company's deoxymab technology aimed at treating hard-to-treat cancers.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Patrys
- Appendix 4C - Quarterly - 30 June 2023
- PAT-DX1 GLP toxicology reports received
- Appendix 4C - Quarterly - 31 March 2023
- Patrys secures US patents for antibody technology
- Two new deoxymab patents granted in the USA
Later from Patrys
- Appendix 4C - Quarterly - 30 September 2023
- GMP Production of PAT-DX1 Next Quarter
- Appendix 4C - Quarterly - 31 December 2023
- Appendix 4D - Half Year Accounts - 31 December 2023
- Positive preclinical data for deoxymabs in vasculitis
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys